Exchange & Returns Information
Review Details
(0)
| Generic For | BOSULIF |
|---|---|
| Active Ingredient | BOSUTINIB |
| Strength | 100MG |
| Manufacturer | MYLAN |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 120 TABLETS | $ 0.56 | $ 67.00 |
$ 56.95
Apply ZARVY26 (-15%)
You save $ 10.05
|
||
| 2 BOXES - 240 TABLETS | $ 0.58 | $ 140.00 |
$ 119.00
Apply ZARVY26 (-15%)
You save $ 21.00
|
||
| ★ Best Value 3 BOXES - 360 TABLETS | $ 0.59 | $ 211.00 |
$ 179.35
Apply ZARVY26 (-15%)
You save $ 31.65
|
Reference information will be available soon.
Bosutris 100 is an oral anticancer medication containing bosutinib, a second-generation tyrosine kinase inhibitor (TKI) specifically indicated for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is particularly valuable for patients who are resistant or intolerant to prior TKIs such as imatinib, dasatinib, or nilotinib.
Bosutris 100 works by blocking both BCR-ABL and SRC family kinases, providing a broader inhibition profile against leukemic pathways. It has been associated with a high rate of major molecular response (MMR) and supports prolonged disease control across the chronic, accelerated, and blast crisis phases of CML.
AntiCancer Drugs > Chronic Myeloid Leukemia (Ph+ CML)
Bosutris 100 is used as a second- or third-line treatment option in patients who have failed or cannot tolerate previous TKIs. It effectively inhibits both BCR-ABL and SRC kinases, and is active against a broad range of resistant mutations, with the exception of T315I.
> Newly Diagnosed CML
In select countries, Bosutris 100 is recognized as a first-line therapy for newly diagnosed Ph+ CML. Its approval is supported by long-term progression-free survival (PFS) data and favorable safety outcomes, making it a viable alternative to other TKIs.
> Advanced-Stage CML (Accelerated Phase & Blast Crisis)
Bosutris 100 is also used as part of salvage therapy strategies for patients whose disease has advanced to the accelerated phase or blast crisis. In these cases, it helps delay disease progression and provides therapeutic stability before more aggressive interventions such as hematopoietic stem cell transplantation (HSCT).
Bosutinib functions as a dual inhibitor targeting both BCR-ABL fusion proteins and SRC family kinases. This dual activity makes it especially valuable in managing resistant Ph+ CML, as it effectively suppresses leukemic cell proliferation and helps restore hematologic and cytogenetic responses.
Its expanded mutation coverage—with the exception of T315I—allows it to be effective in a broader range of resistant cases. Clinical studies have shown that bosutinib delivers durable responses, including in high-risk populations, making it a versatile treatment option across different stages of CML.
For newly diagnosed chronic phase Ph+ CML, the usual adult dose is 400 mg orally once daily with food. Treatment should be continued until disease progression or the development of patient intolerance.
For chronic, accelerated, or blast phase Ph+ CML with prior resistance or intolerance to therapy, the recommended dose is 500 mg orally once daily with food. Therapy should be maintained until disease progression or the occurrence of unacceptable toxicity.
Additional Instructions:
Bosutris 100 must be taken with food to reduce gastrointestinal side effects and improve drug absorption. If more than 12 hours have passed since a missed dose, the dose should be skipped, and the next scheduled dose resumed. Patients should not double the dose. Routine monitoring of liver enzymes and complete blood counts is required during treatment.
Store in a cool, dry environment below 30°C. Keep the tablets in their original packaging to protect from moisture and light. Ensure it is kept out of reach of children.
Most frequently reported adverse effects include diarrhea, nausea, vomiting, and abdominal discomfort. Laboratory abnormalities such as elevated ALT/AST and thrombocytopenia may occur. Less commonly, rash, fatigue, and musculoskeletal pain have been noted. Liver function and hematologic parameters should be monitored throughout the treatment.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
